Anavex Life Sciences Corp. (NASDAQ:AVXL) is a leader in utilizing precision genetic medicine to treat severe neurological diseases with no available therapy, such as Rett syndrome, as well as age-related neurodegenerative diseases such as Alzheimer’s Disease and Parkinson’s Disease.
The pharmaceutical sector has seen some ups and downs in the past several years. Especially with the rise of vaccinations and a bigger focus on health, any medically-related stock is sure to be affected.
This is definitely true of Anavex Life Sciences Corp (NASDAQ:AVXL) as they continue to conduct trials for their drugs Anavex 2-73 (Blarcamesine), Anavex 3-71 (AF710B) and Anavex 1-41.
The first, ANAVEX 2-73 is now in Phase 3 clinical trials to treat Alzheimer’s disease and Rett’s Syndrome. These promising trials may position this company for future success.
However, analysts are generally hesitant to give this stock a buy rating due to its high volatility and low earnings.
Why did Anavex (NASDAQ:AVXL) 30% gain recently?
On June 13, 2021, Anavex Life Sciences (NASDAQ:AVXL) reported a new publication in a medical journal discussing Anavex 2-73 (blarcamesine) and Anavex 3-71 (AF710B) for the treatment of Alzheimer’s disease. The highlights from this scientific paper include:
- How Sigma1 receptors expression increases with age, but decreases in Alzheimer’s patients.
- The drug has been shown to induce autophagy, which is the regrowth of old cells from dead ones.
- How the company’s treatment activates SIGMAR1 , a key receptor in autophagy
In very basic terms, Anavex’s (NASDAQ:AVXL) pharmaceutical compounds may help in reversing neurological degeneration in aging patients. Alzheimer’s disease causes multiple pathways in the brain. Other available treatments usually target a single pathway.
The Bottom Line
Anavex Life Sciences (NASDAQ:AVXL) has risen over the past year as a result of promising clinical trials. Key factors differing the company’s treatments for age-related diseases from others make it a stock to continue to watch as we head into post CV19 recovery. The promise of the company’s new treatments and the completion of Phase 3 trials on some of their offerings have lead to a slow but steady rise in the stock. Will we see this trend continue for Anavex (NASDAQ:AVXL)? Only time will tell.
Featured image: MegaPixl © Molekuul
PLEASE NOTE
Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively herein referred to as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Avanex Life Sciences Corporation; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Avanex’s projects; (vi) completion of Avanex’s projects that are currently underway, in development or otherwise under consideration; (vi) renewal of Avanex’s current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
